Ovarian Cancer Treatment Market
May 13, 2025
Eli Lilly’s ZEPBOUND Surpasses WEGOVY in SURMOUNT-5 Trial; Verastem Oncology Secures FDA Approval for AVMAPKI + FAKZYNJA in KRAS-Mutant Ovarian Cancer; Thermosome Gains Orphan Drug Designation for THE001; Beam Therapeutics Receives RMAT Status for BEAM-302 in AATD; Capsida Biotherapeutics Gets IND Clearance for STXBP1 Gene Therapy
Eli Lilly’s ZEPBOUND Outperforms WEGOVY in SURMOUNT-5 Trial Eli Lilly and Company released detailed results from the Phase IIIb SURMOUNT-5 clinical trial, showing that ZEPBOUND (tirzepatide) significantly outperformed WEGOVY (semaglutide) in weight loss among adults with obesity or overweight and at least one we...
Read More...
May 04, 2020
Altering the course of Ovarian cancer with emerging therapies in the horizon
Many players such as Immunogen, On Target Laboratories, ImmunoVaccine Technologies, OncoQuest, Precigen, and some others are involved in developing therapies to accelerate the Ovarian Cancer Market. Cancer, coronary heart disease, and stroke are the leading contributors of the mortality worldwide, estimated ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
